Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tamoxifen in HR+ Well Differentiated Neuroendocrine Tumors
NCT03870399Phase 2Completed
- Sponsor
- A.C.Camargo Cancer Center
- Start
- Mar 2019
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of tamoxifen in neuroendocrine tumors (NETs), sponsored by A.C.Camargo Cancer Center. Primary endpoint: Disease control rate at 24 weeks. Started Mar 2019; status: completed.
02
Drugs
tamoxifen
03
Conditions
neuroendocrine tumors (NETs)
Beyond the preview
Go deeper on NCT03870399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03870399.